Lipid Management

Introduction to Lipid Management

• Lipid management involves reducing LDL-C levels to prevent cardiovascular disease, with various treatment options available, including statins, ezetimibe, PCSK9 inhibitors, and inclisiran, as recommended by the American College of Cardiology and American Heart Association 1, 2, 3, 4

Statin Therapy

• The American College of Cardiology recommends high-intensity statins (atorvastatin 40-80mg, rosuvastatin 20-40mg) for patients with established ASCVD, aiming for ≥50% LDL-C reduction, with a strength of evidence classified as high 3
• The American College of Cardiology recommends moderate-intensity statins for lower-risk patients, aiming for 30-49% LDL-C reduction, with a strength of evidence classified as moderate 3
• For patients with eGFR <60 mL/min/1.73m², lower doses of statins are recommended (e.g., atorvastatin 20mg, rosuvastatin 10mg), as stated by the American College of Cardiology 5
• Statin therapy is recommended for patients ≥40 years, LDL-C ≥100 mg/dL, and presence of end-organ damage or additional ASCVD risk factors, according to the American College of Cardiology 6
• Statin therapy is not recommended in patients with heart failure in the absence of other indications (Class III recommendation), as stated by the American College of Cardiology 7

Non-Statin Therapies

• Adding ezetimibe 10mg daily to statin therapy is particularly useful for patients not reaching targets on maximum tolerated statin dose, with a strength of evidence classified as moderate, as recommended by the American College of Cardiology 3
• Ezetimibe 10 mg daily is recommended for LDL-C reduction, with monitoring of lipid profile after 4-12 weeks to assess response, and can be combined with other therapies such as bempedoic acid for enhanced effect (approximately 35% LDL-C reduction), as stated by the American College of Cardiology 1, 2, 8, 9, 10, 11
• Monoclonal antibodies (alirocumab, evolocumab) provide 50-60% additional LDL-C reduction, with a strength of evidence classified as high, as recommended by the American College of Cardiology 4
• PCSK9 inhibitors are recommended for patients with very high-risk ASCVD and LDL-C ≥70 mg/dL despite maximally tolerated statin and ezetimibe, with a strength of evidence classified as high, as stated by the American College of Cardiology 4, 3
• Inclisiran is recommended as a non-statin therapy option in addition to maximally tolerated statin therapy for patients at very high risk of ASCVD or with LDL-C levels above a certain threshold, and as an alternative to PCSK9 mAbs in patients with adherence issues, injection difficulties, or adverse effects from PCSK9 mAbs, with a strength of evidence classified as high, as recommended by the American College of Cardiology 12
• Inclisiran provides sustained LDL-C reduction of approximately 45% with twice-yearly dosing, while alirocumab has shown 54.8% LDL-C reduction in statin-intolerant patients compared to 20.1% with ezetimibe, as stated by the American College of Cardiology 13
• Bempedoic acid reduces LDL-C by 15-25% with low rates of muscle-related adverse effects, with a strength of evidence classified as moderate, as recommended by the American College of Cardiology 10, 11

Special Populations

• The American Diabetes Association recommends monoclonal antibodies, such as alirocumab, as a first choice for most statin-intolerant patients, providing a 54.8% LDL-C reduction, with lower skeletal muscle-related adverse events (32.5% vs. 46% with atorvastatin) and lower discontinuation rates (18.3% vs. 25.4% for atorvastatin) in statin-intolerant patients, with a strength of evidence classified as high 13
• PCSK9 inhibitors, such as alirocumab, have shown efficacy in patients with diabetes, providing a significant reduction in LDL-C levels, with a strength of evidence classified as high 13
• Non-dialysis CKD patients should be treated with statins or statin/ezetimibe combination (Class I recommendation), as stated by the American College of Cardiology 7
• Dialysis-dependent CKD patients should not initiate statins, but continue if already on therapy at dialysis initiation, as recommended by the American College of Cardiology 5, 7

Lifestyle Modifications

• The American College of Cardiology, American Diabetes Association, and American Heart Association recommend intensifying lifestyle therapy, including a Mediterranean or DASH eating pattern, regular physical activity, and weight management if indicated, as the first step for patients with statin intolerance, with a strength of evidence classified as high 1, 2, 11, 12
• The American Heart Association recommends reduced intake of saturated fats (<7% of total calories), trans fatty acids (<1% of total calories), and cholesterol (<200 mg/day), with a strength of evidence classified as high 2

LDL-C Targets

• Very high-risk patients should aim for LDL-C <55 mg/dL AND ≥50% reduction from baseline, as recommended by the American College of Cardiology, with a strength of evidence classified as high 4, 7
• High-risk patients should aim for LDL-C <70 mg/dL AND ≥50% reduction from baseline, as stated by the American College of Cardiology, with a strength of evidence classified as high 7
• Moderate-risk patients should aim for LDL-C <100 mg/dL, as recommended by the American College of Cardiology, with a strength of evidence classified as moderate 4, 7
• Low-risk patients should aim for LDL-C <116 mg/dL, as stated by the American College of Cardiology, with a strength of evidence classified as low 4
• LDL-C targets should be adjusted based on the patient's overall cardiovascular risk profile, with consideration of target LDL-C levels based on the patient's risk category, as recommended by the American College of Cardiology, with a strength of evidence classified as high 2, 14, 4, 12
• The American Heart Association recommends LDL-C targets of <70 mg/dL for very high-risk patients, <100 mg/dL for high-risk patients, and non-HDL-C <130 mg/dL for patients with triglycerides ≥200 mg/dL, with a strength of evidence classified as high 2

Guideline Recommendations

15, 11, 16, 17